Equillium announces new aryl hydrocarbon receptor modulator program eq504

La jolla, calif.--(business wire)---- $eq--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced the advancement of a novel and potent aryl hydrocarbon receptor (ahr) modulator (eq504), which was acquired through the acquisition of ariagen, a biotechnology company that was majority owned by equillium's largest investor, decheng capital. ahr.
EQ Ratings Summary
EQ Quant Ranking